[	(
Idiopathic	JJ
pulmonary	JJ
fibrosis	NN
and	CC
lung	NN
cancer	NN
]	)
.	.

It	PRP
is	VBZ
widely	RB
known	VBN
that	IN
patients	NNS
with	IN
idiopathic	JJ
pulmonary	JJ
fibrosis	NN
(	(
IPF	NN
)	)
are	VBP
frequently	RB
associated	VBN
with	IN
lung	NN
cancer	NN
.	.

Although	IN
a	DT
complication	NN
with	IN
lung	NN
cancer	NN
is	VBZ
an	DT
important	JJ
prognostic	JJ
factor	NN
for	IN
IPF	NN
,	,
standard	JJ
treatments	NNS
for	IN
lung	NN
cancer	NN
can	MD
not	RB
be	VB
given	VBN
because	IN
of	IN
IPF	NN
.	.

Especially	RB
,	,
the	DT
administration	NN
of	IN
many	JJ
anticancer	JJ
agents	NNS
is	VBZ
limited	VBN
by	IN
a	DT
complication	NN
with	IN
IPF	NN
,	,
which	WDT
is	VBZ
recognized	VBN
as	IN
a	DT
risk	NN
factor	NN
for	IN
the	DT
development	NN
of	IN
fatal	JJ
lung	NN
injury	NN
in	IN
cancer	NN
chemotherapy	NN
.	.

Epidemiological	JJ
studies	NNS
reveal	VBP
that	IN
cigarette	NN
smoking	NN
and	CC
occupational	JJ
and	CC
environmental	JJ
exposure	NN
to	TO
toxic	JJ
substances	NNS
are	VBP
common	JJ
risk	NN
factors	NNS
for	IN
both	DT
IPF	NN
and	CC
lung	NN
cancer	NN
.	.

It	PRP
has	VBZ
been	VBN
assumed	VBN
that	IN
metaplasia	NN
in	IN
fibrous	JJ
lesions	NNS
is	VBZ
pathologically	RB
a	DT
precancerous	JJ
lesion	NN
,	,
but	CC
it	PRP
is	VBZ
necessary	JJ
to	TO
prove	VB
several	JJ
genetic	JJ
abnormalities	NNS
in	IN
the	DT
process	NN
of	IN
carcinogenesis	NN
in	IN
order	NN
to	TO
clarify	VB
that	DT
.	.

Currently	RB
,	,
several	JJ
genetic	JJ
abnormalities	NNS
in	IN
IPF	NN
,	,
including	VBG
in	IN
p53	NN
,	,
K-ras	NN
,	,
FHIT	NNP
and	CC
transforming	VBG
growth	NN
factor	NN
(	(
TGF	NN
)	)
-	:
beta	NN
1	CD
type	NN
II	CD
receptor	NN
,	,
have	VBP
been	VBN
reported	VBN
.	.

